Positron Emission Tomography and Whole-body Magnetic Resonance Imaging for Metastasis-directed Therapy in Hormone-sensitive Oligometastatic Prostate Cancer After Primary Radical Treatment: A Systematic Review

Hellman, 1995, Oligometastases, J Clin Oncol, 13, 8, 10.1200/JCO.1995.13.1.8 Parker, 2018, Radiotherapy to the primary tumour for newly diagnosed, metastatic prostate cancer (STAMPEDE): a randomised controlled phase 3 trial, Lancet Lond Engl, 392, 2353, 10.1016/S0140-6736(18)32486-3 Gandaglia, 2015, Impact of the site of metastases on survival in patients with metastatic prostate cancer, Eur Urol, 68, 325, 10.1016/j.eururo.2014.07.020 Guckenberger, 2020, Characterisation and classification of oligometastatic disease: a European Society for Radiotherapy and Oncology and European Organisation for Research and Treatment of Cancer consensus recommendation, Lancet Oncol, 21, e18, 10.1016/S1470-2045(19)30718-1 Tosoian, 2017, Oligometastatic prostate cancer: definitions, clinical outcomes, and treatment considerations, Nat Rev Urol, 14, 15, 10.1038/nrurol.2016.175 Gillessen, 2020, Management of patients with advanced prostate cancer: report of the Advanced Prostate Cancer Consensus Conference 2019, Eur Urol, 77, 508, 10.1016/j.eururo.2020.01.012 Phillips, 2020, Outcomes of observation vs stereotactic ablative radiation for oligometastatic prostate cancer: the ORIOLE phase 2 randomized clinical trial, JAMA Oncol, 6, 650, 10.1001/jamaoncol.2020.0147 Sundahl N, Gillessen S, Sweeney C, Ost P. When what you see is not always what you get: raising the bar of evidence for new diagnostic imaging modalities. Eur Urol. In press. https://doi.org/10.1016/j.eururo.2020.07.029. Crawford, 2014, Challenges and recommendations for early identification of metastatic disease in prostate cancer, Urology, 83, 664, 10.1016/j.urology.2013.10.026 Lecouvet, 2018, Use of modern imaging methods to facilitate trials of metastasis-directed therapy for oligometastatic disease in prostate cancer: a consensus recommendation from the EORTC Imaging Group, Lancet Oncol, 19, e534, 10.1016/S1470-2045(18)30571-0 Moher, 2015, Preferred reporting items for systematic review and meta-analysis protocols (PRISMA-P) 2015 statement, Syst Rev, 4, 1, 10.1186/2046-4053-4-1 Ost, 2018, Surveillance or metastasis-directed therapy for oligometastatic prostate cancer recurrence: a prospective, randomized, multicenter phase II trial, J Clin Oncol, 36, 446, 10.1200/JCO.2017.75.4853 Pasqualetti, 2020, [(18)F]Fluorocholine PET/CT-guided stereotactic body radiotherapy in patients with recurrent oligometastatic prostate cancer, Eur J Nucl Med Mol Imaging, 47, 185, 10.1007/s00259-019-04482-6 Bouman-Wammes, 2017, Benefits of using stereotactic body radiotherapy in patients with metachronous oligometastases of hormone-sensitive prostate cancer detected by [18F]fluoromethylcholine PET/CT, Clin Genitourin Cancer, 15, e773, 10.1016/j.clgc.2017.03.009 Cysouw, 2018, Prognostic value of [18F]-fluoromethylcholine positron emission tomography/computed tomography before stereotactic body radiation therapy for oligometastatic prostate cancer, Int J Radiat Oncol Biol Phys, 101, 406, 10.1016/j.ijrobp.2018.02.005 Franzese, 2017, 11C-choline-pet guided stereotactic body radiation therapy for lymph node metastases in oligometastatic prostate cancer, Cancer Invest, 35, 586, 10.1080/07357907.2017.1375116 Gomez-Iturriaga, 2019, Outcomes after a first and/or second salvage treatment in patients with oligometastatic prostate cancer recurrence detected by (18-F) choline PET-CT, Eur J Cancer Care, 28, 10.1111/ecc.13093 Ponti, 2015, Salvage stereotactic body radiotherapy for patients with prostate cancer with isolated lymph node metastasis: a single-center experience, Clin Genitourin Cancer, 13, e279, 10.1016/j.clgc.2014.12.014 Ost, 2020, Surveillance or metastasis-directed therapy for oligometastatic prostate cancer recurrence (STOMP): five-year results of a randomized phase II trial, J Clin Oncol, 38, 10, 10.1200/JCO.2020.38.6_suppl.10 Steuber, 2019, Standard of care versus metastases-directed therapy for PET-detected nodal oligorecurrent prostate cancer following multimodality treatment: a multi-institutional case-control study, Eur Urol Focus, 5, 1007, 10.1016/j.euf.2018.02.015 Siva, 2018, Stereotactic ablative body radiotherapy (SABR) for oligometastatic prostate cancer: a prospective clinical trial, Eur Urol, 74, 455, 10.1016/j.eururo.2018.06.004 Yao, 2010, Expression of prostate-specific membrane antigen (PSMA), increases cell folate uptake and proliferation and suggests a novel role for PSMA in the uptake of the non-polyglutamated folate, folic acid, Prostate, 70, 305, 10.1002/pros.21065 Perera, 2020, Eur Urol, 77, 403, 10.1016/j.eururo.2019.01.049 Kneebone, 2018, Stereotactic body radiotherapy for oligometastatic prostate cancer detected via prostate-specific membrane antigen positron emission tomography, Eur Urol Oncol, 1, 531, 10.1016/j.euo.2018.04.017 Artigas, 2019, 68Ga-PSMA PET/CT-based metastasis-directed radiotherapy for oligometastatic prostate cancer recurrence after radical prostatectomy, World J Urol, 37, 1535, 10.1007/s00345-019-02701-1 Guler, 2018, The feasibility of prostate-specific membrane antigen positron emission tomography(PSMA PET/CT)-guided radiotherapy in oligometastatic prostate cancer patients, Clin Transl Oncol, 20, 484, 10.1007/s12094-017-1736-9 Henkenberens, 2016, (68)Ga-PSMA ligand PET/CT-based radiotherapy in locally recurrent and recurrent oligometastatic prostate cancer : early efficacy after primary therapy, Strahlenther Onkol Organ Dtsch Rontgengesellschaft Al, 192, 431, 10.1007/s00066-016-0982-z Horn, 2019, Eur Urol, 76, 517, 10.1016/j.eururo.2019.03.045 Hurmuz, 2020, Treatment outcomes of metastasis-directed treatment using 68Ga-PSMA-PET/CT for oligometastatic or oligorecurrent prostate cancer: Turkish Society for Radiation Oncology group study (TROD 09-002), Strahlenther Onkol Organ Dtsch Rontgengesellschaft Al, 196, 1034, 10.1007/s00066-020-01660-6 Koerber, 2021, Clinical outcome of PSMA-guided radiotherapy for patients with oligorecurrent prostate cancer, Eur J Nucl Med Mol Imaging, 48, 143, 10.1007/s00259-020-04777-z Ong, 2019, Prostate-specific membrane antigen-positron emission tomography/computed tomography (PSMA-PET/CT)-guided stereotactic ablative body radiotherapy for oligometastatic prostate cancer: a single-institution experience and review of the published literature, BJU Int, 124, 19, 10.1111/bju.14886 Siriwardana, 2017, Initial multicentre experience of 68 gallium-PSMA PET/CT guided robot-assisted salvage lymphadenectomy: acceptable safety profile but oncological benefit appears limited, BJU Int, 120, 673, 10.1111/bju.13919 Oehus, 2020, Efficacy of PSMA ligand PET-based radiotherapy for recurrent prostate cancer after radical prostatectomy and salvage radiotherapy, BMC Cancer, 20, 362, 10.1186/s12885-020-06883-5 Schmidt-Hegemann, 2020, Influence of localization of PSMA-positive oligo-metastases on efficacy of metastasis-directed external-beam radiotherapy-a multicenter retrospective study, Eur J Nucl Med Mol Imaging, 47, 1852, 10.1007/s00259-020-04708-y Bravi, 2020, Long-term outcomes of salvage lymph node dissection for nodal recurrence of prostate cancer after radical prostatectomy: not as good as previously thought, Eur Urol, 78, 661, 10.1016/j.eururo.2020.06.043 Habl, 2017, Oligometastases from prostate cancer: local treatment with stereotactic body radiotherapy (SBRT), BMC Cancer, 22, 361, 10.1186/s12885-017-3341-2 Mazzola R, Francolini G, Triggiani L, et al. Metastasis-directed therapy (SBRT) guided by PET-CT 18F-CHOLINE versus PET-CT 68Ga-PSMA in castration-sensitive oligorecurrent prostate cancer: a comparative analysis of effectiveness. Clin Genitourin Cancer. In press. https://doi.org/10.1016/j.clgc.2020.08.002. Eiber, 2011, Whole-body MRI including diffusion-weighted imaging (DWI) for patients with recurring prostate cancer: technical feasibility and assessment of lesion conspicuity in DWI, J Magn Reson Imaging JMRI, 33, 1160, 10.1002/jmri.22542 Padhani, 2017, METastasis Reporting and Data System for Prostate Cancer: practical guidelines for acquisition, interpretation, and reporting of whole-body magnetic resonance imaging-based evaluations of multiorgan involvement in advanced prostate cancer, Eur Urol, 71, 81, 10.1016/j.eururo.2016.05.033 De Visschere, 2019, A systematic review on the role of imaging in early recurrent prostate cancer, Eur Urol Oncol, 2, 47, 10.1016/j.euo.2018.09.010 Birkhäuser, 2013, Combined ultrasmall superparamagnetic particles of iron oxide-enhanced and diffusion-weighted magnetic resonance imaging facilitates detection of metastases in normal-sized pelvic lymph nodes of patients with bladder and prostate cancer, Eur Urol, 64, 953, 10.1016/j.eururo.2013.07.032 Sawicki, 2019, Prospective comparison of whole-body MRI and 68Ga-PSMA PET/CT for the detection of biochemical recurrence of prostate cancer after radical prostatectomy, Eur J Nucl Med Mol Imaging, 46, 1542, 10.1007/s00259-019-04308-5 Metser, 2019, The contribution of multiparametric pelvic and whole-body MRI to interpretation of 18F-fluoromethylcholine or 68Ga-HBED-CC PSMA-11 PET/CT in patients with biochemical failure after radical prostatectomy, J Nucl Med, 60, 1253, 10.2967/jnumed.118.225185 Lecouvet, 2007, Magnetic resonance imaging of the axial skeleton for detecting bone metastases in patients with high-risk prostate cancer: diagnostic and cost-effectiveness and comparison with current detection strategies, J Clin Oncol, 25, 3281, 10.1200/JCO.2006.09.2940 Eustace, 1997, A comparison of whole-body turboSTIR MR imaging and planar 99mTc-methylene diphosphonate scintigraphy in the examination of patients with suspected skeletal metastases, AJR Am J Roentgenol, 169, 1655, 10.2214/ajr.169.6.9393186 Linton, 2012, Whole-body magnetic resonance imaging and prostate cancer metastases: a new gold standard of detection, but does it help us and at what cost?, Eur Urol, 62, 76, 10.1016/j.eururo.2012.02.059 Glicksman, 2020, [18F]DCFPyL PET-MRI/CT for unveiling a molecularly defined oligorecurrent prostate cancer state amenable for curative-intent ablative therapy: study protocol for a phase II trial, BMJ Open, 10, 10.1136/bmjopen-2019-035959 De Bruycker, 2020, PEACE V—Salvage Treatment of OligoRecurrent nodal prostate cancer Metastases (STORM): a study protocol for a randomized controlled phase II trial, BMC Cancer, 20, 406, 10.1186/s12885-020-06911-4 Mottet, 2020, EAU - ESTRO - ESUR - SIOG guidelines on prostate cancer 2020 Palma, 2019, Stereotactic ablative radiotherapy versus standard of care palliative treatment in patients with oligometastatic cancers (SABR-COMET): a randomised, phase 2, open-label trial, Lancet Lond Engl, 393, 2051, 10.1016/S0140-6736(18)32487-5 Murphy, 2017, “Gotta catch 'em all”, or do we? Pokemet approach to metastatic prostate cancer, Eur Urol, 72, 1, 10.1016/j.eururo.2017.02.036 Vapiwala, 2019, Strategies for evaluation of novel imaging in prostate cancer: putting the horse back before the cart, J Clin Oncol, 37, 765, 10.1200/JCO.18.01927 Calais, 2019, 18F-fluciclovine PET-CT and 68Ga-PSMA-11 PET-CT in patients with early biochemical recurrence after prostatectomy: a prospective, single-centre, single-arm, comparative imaging trial, Lancet Oncol, 20, 1286, 10.1016/S1470-2045(19)30415-2 Farolfi A, Hirmas N, Gafita A, et al. PSMA-PET identifies PCWG3 target populations with superior accuracy and reproducibility when compared to conventional imaging: a multicenter retrospective study. J Nucl Med. In press. https://doi.org/10.2967/jnumed.120.246603. Hofman, 2020, Prostate-specific membrane antigen PET-CT in patients with high-risk prostate cancer before curative-intent surgery or radiotherapy (proPSMA): a prospective, randomised, multicentre study, Lancet Lond Engl, 395, 1208, 10.1016/S0140-6736(20)30314-7 Pouliot, 2020, A prospective phase II/III multicenter study of PSMA-targeted 18F-DCFPyL PET/CT imaging in patients with prostate cancer (OSPREY): a sub-analysis of regional and distant metastases detection rates at initial staging by 18F-DCFPyL PET/CT, J Clin Oncol, 38, 9, 10.1200/JCO.2020.38.6_suppl.9 Hope, 2020, Accuracy of 68Ga-PSMA-11 for pelvic nodal metastasis detection prior to radical prostatectomy and pelvic lymph node dissection: a multicenter prospective phase III imaging study, J Clin Oncol, 38, 5502, 10.1200/JCO.2020.38.15_suppl.5502 Connor, 2020, Survival in oligometastatic prostate cancer—a new dawn or the Will Rogers phenomenon?, JAMA Oncol, 6, 185, 10.1001/jamaoncol.2019.4724